title: The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy.
authors.forename: A
authors.initials: A
authors.lastname: Vazquez-Martin
authors.forename: C
authors.initials: C
authors.lastname: Oliveras-Ferraros
authors.forename: S
authors.initials: S
authors.lastname: del Barco
authors.forename: B
authors.initials: B
authors.lastname: Martin-Castillo
authors.forename: J A
authors.initials: JA
authors.lastname: Menendez
mesh_terms: D000263:Adenylate Kinase / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000517:prevention & control*; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D004789:Enzyme Activation; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008687:Metformin / Q000494:pharmacology / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000263:Adenylate Kinase; D000970:Antineoplastic Agents; D007004:Hypoglycemic Agents; D008687:Metformin; D018719:Erb-b2 Receptor Tyrosine Kinases